United States: Having Your Cake And Eating It Too: Considerations From Broad Claims Without Back-Up Narrow Claims

Co-authored by Eve Du*, Stacy Lewis*

Decision: Mayne Pharm. Int'l Pty. Ltd. v. Merck Sharp & Dohme Co., 927 F.3d 1232 (Fed. Cir. 2019)

Holding: In an inter partes review (IPR) Final Written Decision (FWD), the Patent Trial and Appeal Board (PTAB) found all challenged claims of U.S. Patent No. 6,881,745 (the '745 patent) unpatentable as anticipated or obvious. Merck Sharp & Dohme Corp. v. Mayne Pharm. Int'l Pty Ltd., No. IPR2016-01186, Paper 73 (Dec. 18, 2017).1,2 The Federal Circuit affirmed.

Background:

Mayne owns the '745 patent; on appeal, claims 2, 6, and 9-14 were at issue. Each of those claims requires a pharmaceutical composition consisting essentially of about 100 mg of an azole antifungal drug and at least one polymer having acidic functional groups, wherein the composition exhibits certain pharmacokinetic properties in vivo. Specifically, claims 2, 9, 10, and 11 require that the composition provides a mean CMAX of at least 100 ng/ml, while claims 6, 12, 13, and 14 require a mean AUC of at least 800 ng·h/ml. Mayne Pharm. Int'l Pty. Ltd. v. Merck Sharp & Dohme Co., 927 F.3d 1232, 1235 (Fed. Cir. 2019).

Claim 9, reciting a mean CMAX value, is illustrative:

9. A pharmaceutical composition, consisting essentially of:
about 100 mg of an azole antifungal drug; and
one or more polymer[s] having acidic functional groups; and
optionally one or more additional ingredients selected from the group consisting of a disintegrant, a diluent, a filler, an inert solid carrier, an inert solid matrix, a lubricant, a glidant, a colouring agent, a pigment, a flavour, water, ammonia, an alkaline agent, and methylene chloride,
wherein in vivo the composition provides a mean CMAX of at least 100 ng/ml, after administration in the fasted state.

The '745 patent specification explains that water-insoluble drugs, such as azole antifungal drugs, are difficult to formulate into dosage forms because of their low absorption and poor bioavailability. '745 patent at cols. 1 and 2. The combination of drug and acidic polymer in the '745 patent seeks to remedy these shortcomings. Id. at col. 2, ll. 33-35.

The '745 patent issued on April 19, 2005. Over a decade later, on June 11, 2016, Merck petitioned for an inter partes review of claims 1-3, 5-7, and 9-14 of the '745 patent. Merck Sharp & Dohme Corp. v. Mayne Pharm. Int'l Pty Ltd., IPR2016-01186, Paper 1 (June 11, 2016).

During the IPR proceeding, the PTAB granted Mayne's unopposed motion to amend, canceling claims 1, 3, 5, and 7. Merck, IPR2016-01186, Paper 61 (P.T.A.B. Aug. 30, 2017). The PTAB held that each of the remaining, challenged claims was unpatentable as anticipated or obvious. Merck, IPR2016-01186, Paper 73 (P.T.A.B. Dec. 18, 2017).

In particular, the PTAB found the '745 patent anticipated by Kai3, which discloses administering 100 mg of the azole antifungal drug MFB-1041 to dogs, in solid dispersion with hydroxypropyl methylcellulose phthalate ("HP-55") or carboxymethyl cellulose ("CMEC"). HP-55 and CMEC "are both in the '745 patent as qualifying polymers." Merck, IPR2016-01186, Paper 1, at 25 (June 11, 2016). Relying on Kai's reported pharmacokinetic data in dogs, the PTAB found that MFB-1041 provides a mean CMAX of at least 100 ng/ml and a mean AUC of at least 100 ng·h/ml in vivo after administration in the fasted state. Merck, IPR2016-01186, Paper 10, at 19-20 (P.T.A.B. Dec. 19, 2016). The PTAB ultimately issued a FWD concluding that claims 2, 6, and 9-14 of the '745 patent were unpatentable. Merck, IPR2016-01186, Paper 73 (P.T.A.B. Dec. 18, 2017).

Mayne then appealed to the Federal Circuit.

On appeal, Mayne argued that the PTAB erred in two respects: (1) by instituting review when the petition should have been found time-barred under 35 U.S.C. § 315(b), and (2) by declining to adopt Mayne's and the U.S. District Court for the District of Delaware's4 construction of key claim terms, and instead applying a construction that reads on the prior art. Mayne Pharm., 927 F.3d at 1235. We discuss the second issue in detail. Mayne challenged the PTAB's "broadest reasonable interpretation" of the '745 patent claims and argued that its claims are patentable under Mayne's proffered and narrower constructions. Id. at 1235-36. The Federal Circuit affirmed the PTAB's claim construction and its decision of unpatentability. Id. at 1242.

Reasoning

1. The term "pharmaceutical compositions" is not limited to nontoxic compositions

Mayne argued against the PTAB's finding that Kai anticipates or renders obvious the '745 patent claims, contending that "Kai does not disclose a 'pharmaceutical composition' that consists essentially of a drug" because the MFB-1041 agent of Kai undesirably produces clonic convulsions as a result of serious toxicity. Merck, IPR2016-01186, Paper 8, at 27 (Sept. 19, 2016). Mayne argued that "pharmaceutical composition" means "medical drug" and that the term "drug" denotes a compound having beneficial prophylactic and/or therapeutic properties. Id. at 7, 12. Thus, Mayne argued, MFB-1041 is not a pharmaceutical composition because it is toxic and unsuitable for administration to patients. Id. at 27.

The PTAB rejected this argument because the "broadest reasonable interpretation of 'pharmaceutical compositions' and 'drugs' does not exclude agents with both adverse and beneficial effects." Merck, IPR2016-01186, Paper 10, at 18-20 (P.T.A.B. Dec. 19, 2016).

Agreeing with the PTAB, the Federal Circuit explained that the terms "pharmaceutical composition" and "drug" were not limited to nontoxic compositions in view of their treatment in the '745 patent specification. Mayne Pharm., 927 F.3d at 1241. That is, the specification states that "the term 'drug' will be widely understood and denotes a compound having beneficial prophylactic and/or therapeutic properties when administered to, for example, humans." Id. The specification further comments that "the specific benefits of the pharmaceutical composition . . . have been established by the inventors for azole antifungal drugs, such as itraconazole and saperconazole." Id. (emphasis added). Extrinsic evidence showed that saperconazole is toxic. Id. Thus, the Court concluded, the '745 patent claims encompass a toxic drug and cannot be narrowly construed as limited to nontoxic compositions.

2. "in vivo" is not limited to "in humans"

The next issue on appeal was the scope of the "wherein" clause. Mayne argued that the PTAB erred in failing to limit the claimed pharmacokinetic parameters to humans. Id. Mayne noted that the Delaware district court construed the '745 patent claims as directed to humans only and objected to the PTAB's construction of "in vivo" as including plants and animals. Id. at 1241-42.

The PTAB rejected Mayne's argument and found that the claims did not expressly recite that the pharmacokinetic parameters are specific to humans. Merck, IPR2016-01186, Paper 10, at 11-12 (P.T.A.B. Dec. 19, 2016). The specification states that "the term 'in vivo' in general means in the living body of a plant or animal, and the term 'drug' denotes a compound . . . administered to, for example, humans." Id. (emphasis added).

The Federal Circuit agreed with the PTAB holding that, under the broadest reasonable interpretation, "in vivo" was not limited to humans. Mayne Pharm., 927 F.3d at 1242. First, the Court reasoned that animals were expressly included in the definition of "in vivo" in the specification and thus cannot be excluded by the claims reciting in vivo pharmacokinetic data. Id. Second, while the Court acknowledged that the recited in vivo data stem from a human trial, the Court held that it is improper to import a limitation from an embodiment into the claim. Id. Finally, the Court held that the PTAB did not err by discounting the district court's construction, because the PTAB is not generally bound by a prior judicial construction of a claim term. Id. (citing Power Integrations, Inc. v. Lee, 797 F.3d 1318, 1326 (Fed. Cir. 2015)).

Takeaway: Broad and narrow claims go hand in hand

Prosecutors often try to get broad claims for their clients. But in doing so, they must not forget to pursue additional claims to narrower, commercially important embodiments.

There are two sides to drafting a broad claim. On the one side, a broad claim can provide more scope of protection to the invention. On the other, a broader claim is more likely to overlap with prior art or lack adequate support or enablement and is therefore a more vulnerable target for patentability and validity attacks under 35 U.S.C. §§ 102, 103, or 112.

A prosecutor should balance the costs and benefits of broad claims, without losing track of claiming narrower embodiments that may be commercially important. Claiming narrowly enough to adequately protect the client's rights is important, particularly in a regulated industry like pharmaceuticals where narrow claims may be both valid and infringed. In the present case, one or more narrower claims specifying a human recipient of the pharmaceutical composition and a nontoxic drug may have left Mayne with a stronger patent to defend and enforce.

Besides the claims per se, prosecutors should also be careful of the language and examples they use in the specification. For example, a claim requiring a "nontoxic" drug or composition is better served by a specification that defines or describes what nontoxicity means; alternatively, a patent owner might try relying on extrinsic evidence of nontoxicity. Furthermore, although the case law generally holds that courts cannot import a claim limitation directly from the specification, this rule does not always apply. "[C]laims are construed in light of the specification, and are not limited to a designated 'preferred embodiment' unless that embodiment is in fact the entire invention presented." Vulcan Eng'g Co. v. Fata Aluminum, Inc., 278 F.3d 1366, 1376 (Fed. Cir. 2002). And, regardless, the courts often refer to the language of the specification when construing claims. "The specification is always highly relevant to claim construction and is the single best guide to the meaning of a claim term in dispute." Phillips v. AWH Corp., 415 F.3d 1303, 1315 (Fed. Cir. 2005) (en banc). In the Mayne IPR and appeal, the PTAB and Federal Circuit relied on the definition of "in vivo" and examples of "pharmaceutical compositions" provided in the specification to reject Mayne's proposed construction of these terms.

Thus, just as prosecutors should pursue narrow, commercially important embodiments in the claims (possibly in addition to broader claims), so too should prosecutors draft specifications that support and enable both the broad and narrow claim scope.

Further Considerations

1. Patentable weight of the "wherein clause"

The PTAB held, and the Federal Circuit agreed, that the "wherein" clauses of the '745 patent claims were entitled to patentable weight. Merck, IPR2016-01186, Paper 10, at 8-10 (P.T.A.B. Dec. 19, 2016); see also Mayne Pharm., 927 F.3d at 1242.

All of the pharmacokinetic profile "wherein" clauses require that the parameters be met "in vivo." The patentees specifically define that term in the specification: "The term 'in vivo' in general means in the living body of a plant or animal ...." '745 patent col. 3 ll. 36–37. While it is clear that plants are immaterial to the meaning of the claim because the pharmacokinetic parameters are inapplicable to them, and the term pharmaceutical compositions does not generally mean plant treatments, animals are expressly recited by the definition of in vivo. In light of this statement in the specification, a person of skill would understand the claims to include animals.

Mayne Pharm., 927 F.3d at 1242.

"A 'wherein' clause is not given patentable weight if it merely expresses the intended result of a process, or ... is the intended result of administration of the claimed pharmaceutical composition." Merck, IPR2016-01186, Paper 10, at 9 (P.T.A.B. Dec. 19, 2016), citing Hoffer v. Microsoft Corp., 405 F.3d 1326, 1329 (Fed. Cir. 2005). "But, when the clause states a condition that is material to patentability, it cannot be ignored." Merck, IPR2016-01186, Paper 10, at 9. Because there was evidence of record that not all formulations disclosed in the patent necessarily provide the CMAX or AUC profile recited in the claims, the PTAB concluded that the CMAX and AUC limitations gave "meaning and purpose" to the claims. Id. at 10. Therefore, the "wherein" clauses "meaningfully limit the claims, and are entitled to patentable weight." Id.

This holding serves as a reminder that prosecutors may be able to increase the likelihood a "wherein" clause will be given patentable weight by showing, perhaps in the specification or prosecution history record, that the "wherein" clause is material to patentability.

2. "consisting essentially of"

The claims issued in the '745 patent include the transitional phrase "consisting essentially of." This phrase originated from an Examiner interview, at the Examiner's request. It is not defined in the specification nor is it further described in the prosecution history resulting in the '745 patent. In the Mayne IPR, construction of this phrase appeared in the parties' petition (see Merck, IPR2016-01186, Paper 1, at 14-15) and response (see Merck, IPR2016-01186, Paper 8, at 13-15 (Sept. 19, 2016)), but not in the decisions of the PTAB or the Federal Circuit, because the PTAB found it unnecessary to construe the term.

Nonetheless, comments are appropriate on the transitional phrase "consisting essentially of," which is not often dealt with in judicial decisions. The meaning of "consisting essentially of" is now well-established and signals that a claim is partially open-ended. See MPEP § 2111.03. But where the specification fails to define the basic and novel characteristics of the invention, "consisting essentially of" may be construed as the open-ended term comprising. See, e.g., Ex parte Miller, 2015 WL 1871396, at *2 (P.T.A.B. Apr. 21, 2015).

Every case depends on its own facts and circumstances. But, it may be good practice for prosecutors to describe the basic and novel characteristics of an invention in the specification or prosecution history in support of a "consisting essentially of" transitional phrase. Such description may particularly be necessary when "consisting essentially of" distinguishes a claim over prior art that would anticipate or have rendered obvious the same claim reciting "comprising" language. Perhaps, in the instant case, prosecutors could have clarified that the basic and novel characteristics of the '745 patent invention included a nontoxic drug for administration to humans.

Whether it is providing narrow clams with broad claims or having a description to support different types of transitional phrases, these considerations all suggest the need to have a cascading disclosure in the specification. By doing so, it allows one the opportunity to have fall-back positions built into the application, as one cannot predict the type of disclosure that will be cited against the application during prosecution or raised during litigation.

3. Supplement examination

Following the IPR and appeal, claims 1, 3, 5, and 7 were canceled and claims 2, 6, and 9-14 held unpatentable. Mayne Pharm., 927 F.3d at 1234-35. Although claims 4, 15 and 16 of the '745 patent were untouched by these proceedings, they may still be subject to challenges in the future. Merck contended in its petition that Mayne obtained the '745 patent claims by rewriting the claims of the rejected parent patent with the same specification. Merck, IPR2016-01186, Paper 1, at 9-10.

To build a stronger case in favor of the validity of the remaining claims, Mayne could consider filing a request for supplement examination, citing an appropriate number of litigation, IPR, and Federal Circuit papers. If the USPTO finds a substantial new question of patentability (SNQ), then reexamination will be ordered. Perhaps, Mayne could avail itself of that reexamination to narrow claims 4, 15, and 16 to limit the claims to human use, as supported in the specification, and also to nontoxic drugs, perhaps using a declaration or other form of extrinsic evidence for support.

*Eve Du is a Summer Associate at Finnegan
*Stacy Lewis is a Law Clerk at Finnegan

Footnotes

1. "All challenged claims" remaining were claims 2, 6, and 9-14; independent claims 1, 3, 5, and 7 were canceled during the IPR.

2. The FWD is sealed but its existence was noted in the Patent Owner's Notice of Appeal, Paper 76, at 2, filed Feb. 16, 2018.

3. Toshiya Kai, et al., Oral Absorption Improvement of Poorly Soluble Drug Using Solid Dispersion Technique, 44 Chem. Pharm. Bull. 568-71 (1996) ("Kai").

4. The petition arises out of simultaneous district court litigation over the '745 patent captioned Mayne Pharm Int'l Pty Ltd. v. Merck & Co., Inc. et al., Civil Action No. 15-438-LPS-CJB (D. Del.).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions